Oruka Therapeutics, Inc. (NASDAQ:ORKA) — Market Cap & Net Worth
Market Cap & Net Worth: Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (NASDAQ:ORKA) has a market capitalization of $6.06 Billion ($6.06 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3161 globally and #1112 in its home market, demonstrating a -0.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oruka Therapeutics, Inc.'s stock price $93.55 by its total outstanding shares 66209699 (66.21 Million). Also see Oruka Therapeutics, Inc. balance sheet assets for a full breakdown of the balance sheet.
Oruka Therapeutics, Inc. Market Cap History: 2015 to 2026
Oruka Therapeutics, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $35.77 Billion to $6.19 Billion (-15.73% CAGR). Also see cash efficiency ratio of Oruka Therapeutics, Inc. for how efficiently the company converts equity into cash flow.
Index Memberships
Oruka Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.23% | #76 of 976 |
Weight: Oruka Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oruka Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oruka Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Oruka Therapeutics, Inc. share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ORKA by Market Capitalization
Companies near Oruka Therapeutics, Inc. in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of Oruka Therapeutics, Inc. to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Oruka Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Oruka Therapeutics, Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Oruka Therapeutics, Inc.'s market cap moved from $35.77 Billion to $ 6.19 Billion, with a yearly change of -15.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.19 Billion | +208.64% |
| 2025 | $2.01 Billion | +56.32% |
| 2024 | $1.28 Billion | +76.73% |
| 2023 | $726.43 Million | -28.27% |
| 2022 | $1.01 Billion | +10.23% |
| 2021 | $918.71 Million | -46.38% |
| 2020 | $1.71 Billion | -29.77% |
| 2019 | $2.44 Billion | -3.87% |
| 2018 | $2.54 Billion | -75.56% |
| 2017 | $10.38 Billion | -52.63% |
| 2016 | $21.92 Billion | -38.71% |
| 2015 | $35.77 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Oruka Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.06 Billion USD |
| MoneyControl | $6.06 Billion USD |
| MarketWatch | $6.06 Billion USD |
| marketcap.company | $6.06 Billion USD |
| Reuters | $6.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more